Introduction {#H1-1-ZOI200481}
============

Anxiety is highly prevalent among patients with cancer.^[@zoi200481r1],[@zoi200481r2],[@zoi200481r3]^ Approximately 10% to 19% of adults with cancer experience anxiety during or after cancer treatment.^[@zoi200481r2],[@zoi200481r3],[@zoi200481r4]^ Similarly, 14% to 27% of children with cancer experience anxiety.^[@zoi200481r5],[@zoi200481r6]^ Cancer-related anxiety is multifactorial and may stem from patients' psychologic response to the diagnosis and treatment of cancer and from changes in body image, sexual function, work, and social interactions.^[@zoi200481r1],[@zoi200481r7]^ Anxiety reduces patients' health-related quality of life (HRQoL) and can also reduce treatment adherence.^[@zoi200481r8],[@zoi200481r9],[@zoi200481r10]^ In 2014, the American Society of Clinical Oncology recommended individual and group psychologic interventions, such as cognitive-behavioral therapy, applied relaxation, and pharmacologic approaches, to treat cancer-related anxiety.^[@zoi200481r11]^ Mindfulness, a type of mind and body intervention, was not identified as an intervention for the management of anxiety in these guidelines.^[@zoi200481r11],[@zoi200481r12]^

Mindfulness is a technique whereby a person becomes purposefully cognizant of the present moment and learns to address their thoughts, feelings, and sensations in a nonjudgmental manner.^[@zoi200481r13],[@zoi200481r14]^ Many patients with cancer use mindfulness to manage anxiety, depression, and emotional distress during and after their cancer treatment.^[@zoi200481r15],[@zoi200481r16],[@zoi200481r17],[@zoi200481r18],[@zoi200481r19]^ Several randomized clinical trials (RCTs) conducted during the past decade^[@zoi200481r18],[@zoi200481r19],[@zoi200481r20],[@zoi200481r21],[@zoi200481r22]^ have examined the effect of mindfulness-based interventions on anxiety, depression, psychological distress, and HRQoL in adults with cancer. The results of these trials are conflicting about the effect of mindfulness on anxiety.^[@zoi200481r18],[@zoi200481r20],[@zoi200481r21],[@zoi200481r23]^

Previous systematic reviews have evaluated the associations of mindfulness-based stress reduction (MBSR), a widely used mindfulness-based intervention, with psychologic symptoms and HRQoL among patients with breast cancer.^[@zoi200481r24],[@zoi200481r25],[@zoi200481r26],[@zoi200481r27]^ These reviews did not explore the association of mindfulness with anxiety in other cancer types and did not examine different types of mindfulness-based interventions, such as mindfulness-based cognitive therapy (MBCT) or mindfulness-based cancer recovery (MBCR).^[@zoi200481r24],[@zoi200481r25],[@zoi200481r26],[@zoi200481r27]^ Since the publication of these systematic reviews, several RCTs have been performed. These trials evaluated the effect of various mindfulness-based interventions in patients with cancer.

In light of the growing literature on the use of mindfulness-based interventions for the reduction of anxiety and depression among patients with cancer, we conducted this systematic review and meta-analysis to synthesize the existing evidence. Our primary objective was to determine whether mindfulness-based interventions were associated with reductions in the severity of anxiety in adults and children with cancer. Our secondary objective was to determine whether these associations varied by cancer type, intervention, or methods of the study.

Methods {#H1-2-ZOI200481}
=======

Search Strategy and Identification of Studies {#H2-1-ZOI200481}
---------------------------------------------

Our systematic review was conducted according to an a priori protocol. We searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials, CINAHL, PsycINFO, and SCOPUS from database inception to May 2019 to identify relevant citations of published RCTs, using individualized systematic search strategies for each database. The search strategy was developed by a health sciences librarian and peer reviewed by a second librarian using the Peer Review of Electronic Search Strategies checklist.^[@zoi200481r28]^ The search strategy is presented in eTable 1 in the [Supplement](#note-ZOI200481-1-s){ref-type="supplementary-material"}. We contacted study authors when required to request pertinent unpublished data or seek clarification on study methods or results. Reference lists of narrative and systematic reviews and of the included trials were hand-searched for additional citations. Our findings are reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses ([PRISMA](http://www.equator-network.org/reporting-guidelines/prisma/)) reporting guideline.

Study Selection and Data Extraction {#H2-2-ZOI200481}
-----------------------------------

We included RCTs comprised of a patient population of adults (≥18 years) or children (\<18 years) with cancer or who were undergoing hematopoietic stem cell transplant as a treatment for cancer (≥80% of the study population). Enrolled patients were randomized to mindfulness-based interventions or usual care, waitlist, no intervention, or sham control groups for the management of anxiety. We excluded observational, quasi-randomized, crossover, or cluster-randomized trial designs and trials that did not report any outcomes of interest to this review. We did not restrict inclusion by language or date of publication.

Two reviewers (S.O. and J.Y.) independently evaluated the titles and abstracts. The full text of any citation considered potentially relevant by either reviewer was retrieved and assessed for eligibility. The inclusion of trials in this meta-analysis was determined by agreement of the 2 reviewers with discrepancies resolved by a third reviewer (L.S., A.M.A-S, or R.Z.).

We extracted data from included trials using standardized data extraction forms. Study-level variables included the year of publication and enrollment, country of study, age of participants (adults vs children), cancer diagnosis (breast, prostate, other cancer, or more than 1 cancer type), cancer stage (nonmetastatic, metastatic, or both), the timing of intervention (during cancer treatment, following completion of treatment, or both), selective enrollment of palliative care patients (author defined), presence of anxiety as an eligibility criterion for recruitment (author-defined threshold), characteristics of the intervention and control groups, and anxiety, depression, and HRQoL scores up to 1 month, between 1 and 6 months inclusive, and from 6 months up to 1 year postintervention. We decided a priori to include overall or global HRQoL scores for the data synthesis. General health HRQoL scores were extracted from the studies that did not provide global or overall HRQoL scores.

Outcomes {#H2-3-ZOI200481}
--------

Incorporating recommendations from patients and stakeholders, our primary outcome was self-reported short-term (≤1 month postintervention) severity of anxiety measured by any anxiety assessment scale. For studies that used more than 1 type of anxiety assessment scale, we defined a hierarchy of anxiety assessment scales based on the most prevalent scale used among the included trials to use in the primary analysis (eTable 2 in the [Supplement](#note-ZOI200481-1-s){ref-type="supplementary-material"}). For instance, if a trial reported anxiety using both the Hospital Anxiety and Depression Scale--Anxiety (HADS-A) and the Beck Anxiety Inventory scale, the anxiety scores measured by the HADS-A scale were used for the primary outcome. Our secondary outcomes were medium-term (1 to ≤6 months postintervention) and long-term (\>6 to 12 months postintervention) severity of self-reported anxiety, self-reported severity of depression across all the depression scales used in the included studies, patients' overall or general HRQoL scores assessed by self-reported HRQoL questionnaires, and caregivers' HRQoL scores assessed by self-reported questionnaires in short-, medium-, and long-term follow up.

Intervention and Comparator {#H2-4-ZOI200481}
---------------------------

Mindfulness was defined as a technique in which a person learns to focus attention in the present to become mindful of thoughts, feelings, and sensations and observes them in a nonjudgmental way to achieve greater calmness, physical relaxation, and psychologic balance.^[@zoi200481r13],[@zoi200481r14]^ For our review, we included the mindfulness-based interventions (eg, MBSR, MBCT, MBCR, or mindfulness-based art therapy \[MBAT\]) that use mindfulness as the foundation of a therapeutic intervention instead of as an ancillary component.^[@zoi200481r13],[@zoi200481r14]^ Interventions that include mindfulness as 1 of many elements (eg, yoga, Qigong, and tai chi) were not included because it is difficult to determine the effect of mindfulness in the setting of the physical movement. The control groups in the trials were usual care, waitlist, no intervention, or sham control.

Risk of Bias Assessment {#H2-5-ZOI200481}
-----------------------

We assessed the internal validity of included trials using the Cochrane Collaboration Risk of Bias tool.^[@zoi200481r28],[@zoi200481r29]^ This tool categorizes the overall risk of study bias and consists of 6 domains (ie, sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other sources of bias). Each domain is rated low risk, unclear risk, or high risk. Information regarding the risk of bias was used to guide sensitivity analyses and explore sources of heterogeneity. Discrepancies in assessments between the 2 reviewers were resolved by consensus or by a third reviewer (A.M.A-S. or L.S.), as required.

Statistical Analysis {#H2-6-ZOI200481}
--------------------

We used the standardized mean difference (SMD) to synthesize data across studies, which measured anxiety, depression, or HRQoL using a variety of scales.^[@zoi200481r29]^ Weighted mean difference (WMD) was used to synthesize data for analyses concerning specific anxiety and depression scales. A summary effect estimate less than 0 indicates that the mean score was lower (ie, better) in the mindfulness group compared with the control group. The generic inverse variance method was used to weight the effects. A random-effects model was used for all analyses. We assessed statistical heterogeneity between trials using the *I*^2^ statistic.^[@zoi200481r30]^

For the primary outcome, we evaluated potential publication bias using funnel plot analysis and visual inspection of the forest plot.^[@zoi200481r31]^ In the event of potential publication bias, the trim-and-fill technique was used to determine the effect of potential bias using Comprehensive Meta-analysis software, version 2 (Biostat).^[@zoi200481r32]^ Meta-analyses were conducted using Review Manager, version 5.3.5 (The Cochrane Collaboration). All tests of statistical inference reflect a 2-sided α \< .05.

We evaluated the following factors in subgroup analyses: (1) type of cancer (ie, breast cancer vs mixed cancer population and other cancer types), (2) cancer stage (ie, nonmetastatic vs metastatic vs both nonmetastatic and metastatic), (3) timing of intervention (ie, during cancer treatment vs after cancer treatment vs both during and after cancer treatment), (4) mindfulness-based intervention type (ie, MBCT vs MBSR vs MBCR vs MBAT), (5) group vs nongroup or individual delivery setting, (6) number of weeks of intervention (\<8 weeks vs ≥8 weeks), (7) sequence generation (ie, low vs high or unclear risk of bias), and (8) allocation concealment (low vs unclear or high risk of bias). We determined whether the mindfulness-based intervention effect varied by subgroups using the *P* value for interaction.

Results {#H1-3-ZOI200481}
=======

Our electronic search strategy identified 5686 citations, of which 27 trials met the eligibility criteria ([Figure 1](#zoi200481f1){ref-type="fig"}).^[@zoi200481r16],[@zoi200481r18],[@zoi200481r19],[@zoi200481r20],[@zoi200481r21],[@zoi200481r22],[@zoi200481r33],[@zoi200481r34],[@zoi200481r35],[@zoi200481r36],[@zoi200481r37],[@zoi200481r38],[@zoi200481r39],[@zoi200481r40],[@zoi200481r41],[@zoi200481r42],[@zoi200481r43],[@zoi200481r44],[@zoi200481r45],[@zoi200481r46],[@zoi200481r47],[@zoi200481r48],[@zoi200481r49],[@zoi200481r50],[@zoi200481r51],[@zoi200481r52],[@zoi200481r53],[@zoi200481r54]^ We included 1 additional trial identified through hand searching. One trial by Compen et al^[@zoi200481r21]^ randomized patients to in-person MBCT, internet-based MBCT, and usual care cohorts and thus represented 2 separate analyses, for an overall total of 29 mindfulness-based comparisons (3053 participants). All trials were published as full-text articles in English. These trials were conducted in 13 countries from 4 continents ([Table 1](#zoi200481t1){ref-type="table"}). None of the trials included children or adolescents with cancer. Trials of breast cancer patients were the most common (12 trials \[42.8%\]). Even in trials including more than 1 type of cancer (11 trials), breast cancer was the most common diagnosis in all but 1.^[@zoi200481r21],[@zoi200481r40],[@zoi200481r44],[@zoi200481r49],[@zoi200481r51],[@zoi200481r53]^

![Flow Diagram of Trial Identification and Selection](jamanetwopen-3-e2012598-g001){#zoi200481f1}

###### Characteristics of 28 Studies Included in the Systematic Review

  Source; Country[^a^](#zoi200481t1n1){ref-type="table-fn"}          Age range, y   Cancer diagnosis   Cancer stage                   Timing        Total patients, No.   Intervention                                                                  
  ------------------------------------------------------------------ -------------- ------------------ ------------------------------ ------------- --------------------- -------------------------------------- ------------ ------------------------- -----------
  Liu et al,^[@zoi200481r33]^ 2019; China                            NA             Thyroid            Nonmetastatic                  On therapy    120                   MBSR                                   Group        In-person                 8
  Franco et al,^[@zoi200481r34]^ 2019; Spain                         NA             Breast             NA                             NA            36                    Mindfulness-based program              Group        In-person                 7
  Compen et al,^[@zoi200481r21]^ 2018; the Netherlands               NA             \>1                Nonmetastatic and metastatic   Both          116                   MBCT and eMBCT                         Group        In-person and web-based   8
  Lorca et al,^[@zoi200481r35]^ 2018; Spain                          NA             \>1                NA                             Both          108                   Mindfulness-based program              Individual   CD                        50-60 min
  Russell et al,^[@zoi200481r36]^ 2018; Australia                    22-78          Melanoma           Nonmetastatic                  Off therapy   69                    Mindfulness-based program              Nongroup     Web-based                 6
  Chambers et al,^[@zoi200481r37]^ 2017; Australia and New Zealand   NA             Prostate           Nonmetastatic and metastatic   Both          189                   MBCT                                   Group        In-person                 8
  Kenne et al,^[@zoi200481r38]^ 2017; Sweden                         34-80          Breast             NA                             Off therapy   120                   MBSR                                   Group        In-person                 8
  Schellekens et al,^[@zoi200481r39]^ 2017; the Netherlands          NA             Lung               Nonmetastatic and metastatic   Both          63                    MBSR                                   Group        In-person                 8
  Zhang et al,^[@zoi200481r22]^ 2017; China                          17-71          Leukemia           NA                             On therapy    65                    Mindfulness-based psychological care   Nongroup     In-person                 5
  Zhang et al,^[@zoi200481r19]^ 2017; China                          30-62          Breast             Nonmetastatic                  Off therapy   60                    MBSR                                   Group        In-person                 8
  Blaes et al,^[@zoi200481r40]^ 2016; United States                  36-79          \>1                Nonmetastatic                  Off therapy   42                    MBCR                                   Group        In-person                 8
  Jang et al,^[@zoi200481r41]^ 2016; Korea                           NA             Breast             Nonmetastatic                  Off therapy   24                    MBAT                                   Group        In-person                 12
  Johannsen et al,^[@zoi200481r42]^ 2016; Denmark                    NA             Breast             Nonmetastatic                  Off therapy   129                   MBCT                                   Group        In-person                 8
  Lengacher et al,^[@zoi200481r18]^ 2016; United States              NA             Breast             Nonmetastatic                  Off therapy   322                   MBSR                                   Group        In-person                 6
  Vaziri et al,^[@zoi200481r20]^ 2016; Iran                          NA             Breast             Nonmetastatic                  On therapy    20                    MBCT                                   Group        NA                        8
  Bower et al,^[@zoi200481r43]^ 2015; United States                  28.4-60        Breast             Nonmetastatic                  Off therapy   71                    Mindful awareness practices            Group        In-person                 6
  Johns et al,^[@zoi200481r44]^ 2015; United States                  NA             \>1                Nonmetastatic and metastatic   Off therapy   35                    MBSR                                   Group        In-person                 7
  Kingston et al,^[@zoi200481r45]^ 2015; Ireland                     NA             \>1                NA                             Both          16                    MBCT                                   Group        In-person                 8
  Zernicke et al,^[@zoi200481r46]^ 2014; Canada                      29-79          \>1                Nonmetastatic and metastatic   Off therapy   62                    MBCR                                   Group        Web-based                 8
  Würtzen et al,^[@zoi200481r47]^ 2013; Denmark                      NA             Breast             Nonmetastatic                  Both          336                   MBSR                                   Group        In-person                 8
  Hoffman et al,^[@zoi200481r16]^ 2012; United Kingdom               18-80          Breast             Nonmetastatic                  Off therapy   229                   MBSR                                   Group        In-person                 8
  Henderson et al,^[@zoi200481r48]^ 2013; United States              NA             Breast             Nonmetastatic                  Both          111                   MBSR                                   Group        In-person                 20
  Lerman et al,^[@zoi200481r49]^ 2012; United States                 NA             \>1                NA                             Both          77                    MBSR                                   Group        In-person                 8
  Bränström et al,^[@zoi200481r50]^ 2010; Sweden                     NA             \>1                NA                             NA            85                    MBSR                                   Group        In-person                 8
  Foley et al,^[@zoi200481r51]^ 2010; Australia                      24-78          \>1                Nonmetastatic and metastatic   NA            115                   MBCT                                   Group        In-person                 8
  Lengacher et al,^[@zoi200481r52]^ 2009; United States              NA             Breast             Nonmetastatic                  Off therapy   84                    MBSR                                   Group        In-person                 6
  Monti et al,^[@zoi200481r53]^ 2006; United States                  26-82          \>1                Nonmetastatic and metastatic   Both          111                   MBAT                                   Group        In-person                 8
  Speca et al,^[@zoi200481r54]^2000; Canada                          NA             \>1                Nonmetastatic and metastatic   Both          109                   MBSR                                   Group        In-person                 7

Abbreviations: eMBCT, web-based mindfulness-based cognitive therapy; MBAT, mindfulness-based art therapy; MBCR, mindfulness-based cancer recovery; MBSR, mindfulness-based stress reduction; NA, not available.

All included trials were conducted among adults.

The 2 most common mindfulness-based interventions used in the trials were MBSR (13 trials \[46.4%\]) and MBCT (6 trials \[24.1%\]). Trials used usual care (14 trials) and waitlist (14 trials) equally as comparators. The median duration of intervention was 8 weeks (range, 1 hour to 20 weeks). Anxiety assessment scales used across all included trials are listed in eTable 2 in the [Supplement](#note-ZOI200481-1-s){ref-type="supplementary-material"}. Among the 12 reported anxiety scales, the 2 most common scales were the HADS-A (5 trials) and the State-Trait Anxiety Inventory (STAI; 5 trials).

The risk of bias assessment is presented in eFigure 1 in the [Supplement](#note-ZOI200481-1-s){ref-type="supplementary-material"}. As participants and outcome assessors could not be blinded because of the nature of the interventions and patient-reported anxiety outcome, all trials were considered at a high risk of performance and detection bias.

Primary Outcome {#H2-7-ZOI200481}
---------------

Mindfulness-based interventions were associated with reductions in the severity of short-term anxiety (23 trials; 2339 participants; SMD, −0.51; 95% CI, −0.70 to −0.33; *I*^2^ = 76%) ([Figure 2](#zoi200481f2){ref-type="fig"}). Similar results were found when limiting the analysis to trials that measured anxiety using the HADS-A (6 trials; 503 participants; WMD, −1.03; 95% CI, −1.82 to −0.23; *I*^2^ = 32%) or STAI scales (5 trials; 580 participants; WMD, −4.00; 95% CI, −5.21 to −2.78; *I*^2^ = 80%). On sensitivity analysis, the effect estimate was reduced (22 trials; 2231 participants; SMD, −0.46; 95% CI, −0.64 to −0.29; *I*^2^ = 72%) when the trial by Lorca et al^[@zoi200481r35]^ was excluded because of the very short duration of the intervention (50-60 minutes). Examination of the funnel plot for the primary outcome showed the potential absence of small-size studies showing no effect of mindfulness; however, no statistically significant evidence of publication bias was present using trim-and-fill methods (eFigure 2 in the [Supplement](#note-ZOI200481-1-s){ref-type="supplementary-material"}).

![Forest Plot of Association of Mindfulness-Based Interventions With Anxiety in the Short Term, Medium Term, and Long Term\
The size of the square reflects study's relative weight, and the diamond represents the aggregate standardized mean difference and 95% CI. Studies that have multiple listed entries perform multiple analyses between distinct patient groups.](jamanetwopen-3-e2012598-g002){#zoi200481f2}

[Table 2](#zoi200481t2){ref-type="table"} illustrates the a priori subgroup analyses performed to explore heterogeneity in the association of mindfulness with a reduction in short-term anxiety. Subgroup analyses that included the type and stage of cancer, timing of treatment, intervention type, duration of treatment, delivery setting, number of weeks of intervention, and the presence of adequate randomization or allocation concealment could not explain the heterogeneity in the effect of mindfulness ([Table 2](#zoi200481t2){ref-type="table"}).

###### Association of Mindfulness-Based Interventions With Short-Term Anxiety by Patient, Intervention, and Methodological Factors in 28 Included Studies

  Subgroup                                 Trials, No.   Patients, No.   SMD (95% CI)             *I*^2^, %                                      *P* value for interaction
  ---------------------------------------- ------------- --------------- ------------------------ ---------------------------------------------- ---------------------------
  Type of cancer                                                                                                                                 
  Breast                                   10            1224            −0.40 (−0.62 to −0.17)   68                                             .33
  \>1 Cancer and other cancer types        14            1115            −0.57 (−0.86 to −0.29)   76                                             
  Cancer stage                                                                                                                                   
  Nonmetastatic                            10            1209            −0.52 (−0.73 to −0.31)   69                                             .31
  Metastatic                               0             0               NA                                                                      
  Metastatic and nonmetastatic             7             686             −0.36 (−0.55 to −0.16)   37                                             
  Timing of intervention                                                                                                                         
  During cancer treatment                  3             183             −1.16 (−1.94 to −0.38)   78                                             .19
  After cancer treatment                   9             966             −0.43 (−0.70 to −0.17)   71                                             
  Both during and after cancer treatment   9             989             −0.39 (−0.68 to −0.11)   76                                             
  Intervention type                                                                                                                              
  Mindfulness-based stress reduction       11            1376            −0.32 (−0.49 to −0.14)   57                                             .52
  Mindfulness-based cognitive therapy      7             604             −0.32 (−0.53 to −0.12)   31                                             
  Mindfulness-based art therapy            2             117             −1.41 (−3.36 to 0.54)    91                                             
  Mindfulness-based cancer recovery        1             33              −0.78 (−1.64 to 0.08)    NA[^a^](#zoi200481t2n1){ref-type="table-fn"}   
  Delivery setting                                                                                                                               
  Group                                    21            2067            −0.39 (−0.54 to −0.24)   60                                             .07
  Nongroup                                 3             272             −1.19 (−2.05 to −0.34)   90                                             
  Length of intervention, wks                                                                                                                    
  \<8                                      7             715             −0.78 (−1.27 to −0.29)   88                                             .14
  ≥8                                       17            1624            −0.39 (−0.57 to −0.21)   71                                             
  Adequate sequence generation                                                                                                                   
  Yes                                      18            2028            −0.43 (−0.61 to −0.26)   71                                             .23
  Unclear                                  6             311             −0.83 (−1.46 to −0.21)   82                                             
  Adequate allocation concealment                                                                                                                
  Yes                                      10            1361            −0.36 (−0.54 to −0.17)   63                                             .32
  Unclear                                  14            978             −0.68 (−1.02 to −0.34)   76                                             

Abbreviations: NA, not applicable; SMD, standardized mean difference.

*I*^2^ is not calculated here because only 1 study reported this outcome.

Secondary Outcomes {#H2-8-ZOI200481}
------------------

Mindfulness-based interventions reduced the severity of medium-term (1 to 6 months postintervention) anxiety (9 trials; 965 participants; SMD, −0.43; 95% CI, −0.68 to −0.18; *I*^2^ = 66%) ([Figure 2](#zoi200481f2){ref-type="fig"}). Mindfulness-based interventions were not associated with a long-term (\>6 months to 1 year postintervention) reduction in anxiety (2 trials; 403 participants; SMD, −0.02; 95% CI, −0.38 to 0.34; *I*^2^ = 68%) ([Figure 2](#zoi200481f2){ref-type="fig"}).

Mindfulness-based interventions were associated with reductions in the severity of short-term depression (19 trials; 1874 participants; SMD, −0.73; 95% CI, −1.00 to −0.46; *I*^2^ = 86%) ([Figure 3](#zoi200481f3){ref-type="fig"}) and medium-term depression (8 trials; 891 participants; SMD, −0.85; 95% CI, −1.35 to −0.35; *I*^2^ = 91%) ([Figure 3](#zoi200481f3){ref-type="fig"}). The list of all depression assessment scales used in the included trials is provided in eTable 3 in the [Supplement](#note-ZOI200481-1-s){ref-type="supplementary-material"}. Mindfulness-based interventions were associated with a reduction in depression when the analysis was limited to trials reporting the HADS-D (5 trials; 396 participants; WMD, −1.16; 95% CI, −1.94 to −0.38; *I*^2^ = 54%). Mindfulness was not associated with a reduction in the severity of depression in the long term (2 trials; 349 participants; SMD, −0.96; 95% CI, −2.38 to 0.46; *I*^2^ = 97%) ([Figure 3](#zoi200481f3){ref-type="fig"}).

![Forest Plot of Association of Mindfulness-Based Interventions With Depression in Short Term, Medium Term, and Long Term\
The size of the square reflects study's relative weight, and the diamond represents the aggregate standardized mean difference and 95% CI. Studies that have multiple listed entries perform multiple analyses between distinct patient groups.](jamanetwopen-3-e2012598-g003){#zoi200481f3}

Mindfulness-based interventions were associated with improved overall HRQoL scores in the short term (9 trials; 1108 participants; SMD, 0.51; 95% CI, 0.20 to 0.82; *I*^2^ = 82%) and medium term (5 trials; 771 participants; SMD, 0.29; 95% CI, 0.06 to 0.52; *I*^2^ = 57%). The included HRQoL assessment scales are listed in eTable 4 in the [Supplement](#note-ZOI200481-1-s){ref-type="supplementary-material"}. The only trial reporting the effect of mindfulness on long-term HRQoL did not demonstrate any improvement in HRQoL (1 trial; 153 participants; WMD, 0.78; 95% CI, −5.98 to 7.54). None of the included trials reported caregivers' HRQoL.

Discussion {#H1-4-ZOI200481}
==========

In this systematic review and meta-analysis, we found that mindfulness-based interventions were associated with reductions in the severity of anxiety in the short term and medium term, but not in the long term, among adults with cancer. Mindfulness was associated with a significant improvement in short-term and medium-term, but not in long-term, depression or HRQoL.

Our study builds on previously published systematic reviews.^[@zoi200481r24],[@zoi200481r25],[@zoi200481r26],[@zoi200481r27]^ We incorporated diverse mindfulness-based interventions across all cancer populations, whereas the majority of the published systematic reviews were narrowly focused on MBSR interventions in patients with breast cancer.^[@zoi200481r24],[@zoi200481r26],[@zoi200481r27]^ The only published systematic review examining various types of mindfulness interventions across different cancer diagnoses in adults included only 9 trials and did not use rigorous methods for meta-analysis and assessing the quality of included trials.^[@zoi200481r55]^ In contrast, we used robust methods for identifying trials and synthesizing data. Our review identified a larger number of trials, synthesized the effect of treatment at various time points, and assessed subgroup differences and the risk of bias across included studies. The larger sample size improved the precision of the effect estimates and enabled us to perform subgroup analysis to explore heterogeneity.

An SMD of 0.51 suggests a moderate reduction in short-term anxiety associated with mindfulness.^[@zoi200481r56],[@zoi200481r57]^ This association with reduction in short-term anxiety remained significant even when studies using the HADS-A and STAI were analyzed separately. The minimum clinically important difference (MCID) associated with HADS-A and STAI has not been identified for patients with cancer in the literature. The reported MCID for HADS-A among patients with chronic obstructive pulmonary disease is 1.5.^[@zoi200481r58]^ If we extrapolate the MCID of the HADS-A scale from patients with chronic obstructive pulmonary disease to patients with cancer, the observed reduction in short-term anxiety on the HADS-A scale (1.03) is lower than the clinically meaningful threshold. Similar to anxiety, the observed short-term association of mindfulness with depression could not reach a clinically significant threshold. However, it should be noted that behavioral therapies, recommended by American Society of Clinical Oncology as 1 of the modalities for the treatment of anxiety and depression in adults with cancer, are associated with small to moderate effect sizes, similar to mindfulness-based interventions.^[@zoi200481r11],[@zoi200481r59]^ Furthermore, mindfulness-based interventions also positively affect other symptoms, such as fatigue, distress, and pain in patients with cancer.^[@zoi200481r60],[@zoi200481r61]^ Therefore, we suggest that mindfulness-based interventions should be considered an effective treatment option for reducing short-term and medium-term anxiety among adults with cancer. Comparing mindfulness-based interventions with other effective interventions for anxiety, such as drugs and behavioral therapies, should be the focus of future research in adults with cancer.

We also demonstrated that, in the longer term, mindfulness-based interventions were associated with little or no benefit on anxiety, depression, or quality of life. Our confidence in the long-term effects of mindfulness-based interventions is low because only 2 trials reported the long-term effects of mindfulness. It is plausible that the absence of booster or follow-up sessions after an initial 8 to 12 weeks of intervention might have diminished the durability of effect. As mindfulness is a skill-building approach, booster sessions may provide participants with the opportunity to master difficult skills and to generalize the mindfulness skills to newly encountered situations in life.

The effect of mindfulness on short-term anxiety did not differ by the assessed patient, intervention, and study characteristics. Specifically, the short-term benefits of mindfulness on anxiety were dependent neither on the type of cancer nor on the treatment phase. These results suggest that examined mindfulness-based interventions could result in the reduction of short-term anxiety of adults regardless of cancer type or stage of treatment. Furthermore, the association of mindfulness with reductions in short-term anxiety was not restricted to studies providing 8 weeks or more of mindfulness and group sessions; instead, the reduction in anxiety was marginally higher when mindfulness was delivered in the individual setting. In clinical practice, mindfulness-based interventions are typically offered in a group setting during an 8-week period.^[@zoi200481r21],[@zoi200481r26],[@zoi200481r37]^ The longer-duration group sessions can be challenging for patients who either have complications related to cancer or are on active treatment. Young adults with cancer who are well connected with technology may also prefer shorter mindfulness sessions delivered by telehealth, video-interface, or a mobile application.^[@zoi200481r62]^ Our findings suggest that individually delivered or shorter duration mindfulness-based interventions can be offered to the patients with cancer who cannot commit to group sessions or 8 weeks of intervention due to their illnesses or other barriers.

Limitations {#H2-9-ZOI200481}
-----------

Our systematic review has limitations that deserve comment. We cannot be certain that the observed treatment gains were exclusively due to the mindfulness intervention and not because of the facilitator's attention, group support, and social interaction, given that none of the trials included an attention control group that matched the intervention group on all of these elements. These nonspecific factors are inherent components of the mindfulness intervention and can potentially affect the outcome. Women were overrepresented in the trials with mixed cancer populations,^[@zoi200481r21],[@zoi200481r49],[@zoi200481r51],[@zoi200481r53]^ and 43% of included trials were done in patients with breast cancer who had completed curative treatment. The effect size for men in the gender-inclusive trials was not reported separately.^[@zoi200481r21],[@zoi200481r49],[@zoi200481r51],[@zoi200481r53]^ The only trial that exclusively enrolled men with advanced prostate cancer did not show any reduction in anxiety.^[@zoi200481r37]^ Men may be less receptive and responsive to mindfulness because of their different coping mechanisms than women.^[@zoi200481r63]^ Therefore, further investigation of how gender affects the efficacy of mindfulness is warranted. There was also no representation of patients in palliative care or undergoing hematopoietic stem cell transplant in the included trials. None of the included trials were conducted in children or in patients with metastatic disease exclusively. Consequently, the results of this meta-analysis may not be generalizable to all cancer populations and settings. Most included trials did not use standardized tools to measure the total time spent practicing mindfulness per week or reported changes in the mindfulness. These factors may explain the heterogeneity in the measured effect, which subgroup analysis did not demonstrate. Other unmeasured patient characteristics in the included trials may also have contributed to the heterogeneity. Finally, imprecision, related to the small sample size, limited our confidence in the long-term effects of mindfulness-based interventions on the studied outcomes.

Conclusions {#H1-5-ZOI200481}
===========

In this study, mindfulness-based interventions were associated with short-term and medium-term reductions in anxiety and depression along with improved quality of life among adult patients with cancer. Future studies should assess the efficacy of mindfulness in different settings, include diverse cancer populations such as children and men, and compare mindfulness with other effective interventions for anxiety and depression.
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